Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | HTR7 | P34969 | 3/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3682972 | 0.92 | CDK4 (0.30) | — | |
| SCHEMBL3698490 | 0.89 | ALDH1A1 (0.38) | TDP1DRD2MAPTL3MBTL1HPGD | |
| SCHEMBL3680438 | 0.86 | — | — | |
| SCHEMBL1195613 | 0.85 | ALOX5 (0.36) | HTR2AHTR7L3MBTL1HPGDMAPK1 | |
| SCHEMBL16390545 | 0.84 | NPC1 (0.37) | CYP2C19MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL3682970 | 0.82 | — | — | |
| SCHEMBL135939 | 0.82 | MAPT (0.32) | MAPT | |
| SCHEMBL29365624 | 0.82 | MAPT (0.32) | MAPT | |
| Hydrochloric Acid SCHEMBL2833170 | 0.81 | MAPT (0.32) | MAPT | |
| Methane SCHEMBL23781973 | 0.80 | HTT (0.33) | TDP1MAPTL3MBTL1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718849-B2 | Sulfur chelated ruthenium compounds useful as olefin metathesis catalysts | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2017-08-01 | — | — | US | disclosed |
| US-20140155511-A1 | SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2014-06-05 | — | — | US | disclosed |
| US-8513151-B2 | Sulfur chelated ruthenium compounds useful as olefin metathesis catalysts | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IS) | 2013-08-20 | — | — | US | disclosed |
| US-20100113722-A1 | SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2010-05-06 | — | — | US | disclosed |
| US-20090156766-A1 | Sulfur chelated ruthenium compounds useful as olefin metathesis catalysts | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156766-A1 | Sulfur chelated ruthenium compounds useful as olefin metathesis catalysts | TST, MPST, NISCH | TDP1 3185/4885CYP2D6 833/4885CYP2C19 2867/4885 |
| US-20140155511-A1 | SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS | C1S, SCO2, AP1S1 | TDP1 4270/4885CYP2D6 513/4885CYP2C19 2412/4885 |
| US-20100113722-A1 | SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS | C1S, SCO2, AP1S1 | TDP1 4270/4885CYP2D6 513/4885CYP2C19 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.